Efficacy
Forty-six pts were evaluable for efficacy parameters. The cumulative confirmed MMR rate (95% CI) by 1 year was 68% (54–78%, see Fig. Probabilities of MMR, MRSix out of 7 intolerant pts without MMR at baseline reached MMR or a better molecular response level with bosutinib. Thirty pts refractory to previous therapy (19 being resistant; 11 being resistant and intolerant) were lacking baseline MMR, of which 19 pts achieved MMR or better (2 pts with MR4.5, 2 with MR4 and 15 with MMR). In the 30 refractory pts without MMR at baseline, the cumulative MMR rate by 1 year was 46% (27–62%) and MR4 and MR4.5 rates were 11% (3–25%) and 4% (0–16%), respectively (Fig. Molecular response (MR) rates and probabilities of molecular response at 3, 6, 12, 18, and 24 monthsLegend: At baseline, 20 pts (35%) had entered the study in MMR, 8 pts (14%) were already in MR4, and 3 pts (5%) were already in MR4.5. Median time to MMR was 4.4 months and median time to MR4 was 18 monthsMedian bosutinib dose according to level of molecular responseLegend: Forty patients received bosutinib up to 6 months and also had a 6-month molecular response evaluation (Min, Median Max: minimum, median, and maximum bosutinib dosage within the first 6 months; 